retatrutide
Peptide
Also known as LY3437943
Evidence outlook · lead readout
TRIUMPH-2 (NCT05929079) · Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint. Separately, the sponsor reported topline results of NCT05882045 on 2026-07-23 (TRIUMPH-3 (NCT05882045) Phase 3 met its primary endpoint); NCT05882045 is graded under Featured trials, and the announcement is listed under Regulatory events.
TRIUMPH-2 (NCT05929079): TRIUMPH-2 was a randomized, double-blind, placebo-controlled Phase 3 trial in 1,152 adults with obesity or overweight and type 2 diabetes, who received weekly retatrutide 4 mg, 9 mg or 12 mg or placebo. The primary endpoint was the percent change in body weight at week 80 with the 9 mg and 12 mg doses against placebo. Weight fell by 16.8% and 18.8% against 5.1% with placebo (p<0.0001 for both), so the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet.
Also in development:Type 2 Diabetes · Phase 3Atherosclerotic Cardiovascular Disease · Phase 3Chronic Kidney Disease · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
TRIUMPH-3 NCT05882045 · Obesity The study was randomized, double-blind, and placebo-controlled, with 1,946 participants enrolled, and its primary endpoint was the clinical obesity outcome of percent change in body weight. The primary comparison favored retatrutide and met its primary endpoint per the sponsor's topline release (no p-value published), but no power calculation or planned enrollment target is provided in the available record, so the evidence is graded moderate rather than strong. Registry: NCT05882045 | 3 | Percent Change from Baseline in Body Weight (Baseline, Week 80) 2026-04-16 | Primary endpoint, percent change in body weight at 80 weeks (efficacy estimand): retatrutide 9 mg -21.6% and 12 mg -22.6% vs placebo -3.2%; the sponsor reports the primary endpoint met. | Partial signal | link ↗ |
View 4 more trials
NCT04881760 NCT04881760 · Obesity, Overweight The trial randomized 338 participants to double-blinded weekly LY3437943 or matched placebo. Its primary clinical endpoint, mean percent change in body weight at Week 24, was significantly favorable for every LY3437943 dose compared with placebo (all p<0.001), supporting a strong evidence grade. Registry: NCT04881760 | 2 | Mean Percent Change From Baseline in Body Weight (Baseline, Week 24) 2022-05-16 | Mean Percent Change From Baseline in Body Weight (Baseline, Week 24): 1 mg LY3437943 -7.18% (Standard Error 0.67) | 4 mg LY3437943 (2 mg) -12% (Standard Error 0.71) | 4 mg LY3437943 -13.8% (Standard Error 0.97) | 8 mg LY3437943 (2 mg) -16.64% (Standard Error 0.74) | 8 mg LY3437943 (4 mg) -18.26% (Standard Error 0.95) | 12 mg LY3437943 (2 mg) -17.39% (Standard Error 0.69) vs Placebo -1.55% (Standard Error 0.54) | Reliable signal | link ↗ |
TRIUMPH-1 NCT05929066 · Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea TRIUMPH-1 was a randomized, double-blind, placebo-controlled Phase 3 trial in 2,339 adults with obesity and without diabetes, who received weekly retatrutide 4 mg, 9 mg or 12 mg or placebo for 80 weeks. The primary endpoints compared the 9 mg and 12 mg doses with placebo on percent weight change, on knee pain (WOMAC) in 574 participants with knee osteoarthritis, and on the apnea-hypopnea index in 243 participants with obstructive sleep apnea. Weight fell by 23.7% and 25.0% against 3.9% with placebo, and both doses also reduced knee pain and sleep apnea events significantly (P<0.001 for all comparisons), so the trial met its primary endpoints. The figures come from the peer-reviewed paper in the New England Journal of Medicine. Registry: NCT05929066 | 3 | Percent change in body weight to week 80 (9 mg and 12 mg vs placebo); WOMAC pain change in the knee osteoarthritis subgroup; apnea-hypopnea index change in the obstructive sleep apnea subgroup 2026-04-06 | Primary 1, percent change in body weight to week 80 (treatment-regimen estimand): retatrutide 9 mg -23.7% and 12 mg -25.0% vs placebo -3.9% (differences -19.8 and -21.0 percentage points; P<0.001 for both), met (4 mg -17.6%, not a primary comparison). Primary 2, WOMAC pain change in the knee osteoarthritis subgroup (hybrid estimand): 9 mg -3.5 and 12 mg -3.6 vs placebo -1.9 (differences -1.6 and -1.8 points; both P<0.001), met. Primary 3, apnea-hypopnea index change in the sleep apnea subgroup (hybrid estimand): differences vs placebo -24.4 (9 mg) and -21.9 (12 mg) events per hour; both P<0.001, met. The registered week-104 weight primary in the extension subset is not reported in the paper abstract. | Partial signal | link ↗ |
TRIUMPH-2 NCT05929079 · Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea TRIUMPH-2 was a randomized, double-blind, placebo-controlled Phase 3 trial in 1,152 adults with obesity or overweight and type 2 diabetes, who received weekly retatrutide 4 mg, 9 mg or 12 mg or placebo. The primary endpoint was the percent change in body weight at week 80 with the 9 mg and 12 mg doses against placebo. Weight fell by 16.8% and 18.8% against 5.1% with placebo (p<0.0001 for both), so the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet. Registry: NCT05929079 | 3 | Percent Change from Baseline in Body Weight (Baseline, Week 80); Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset (Baseline, Week 80) 2026-06-16 | Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract. | Reliable signal | link ↗ |
TRIUMPH-4 NCT05931367 · Obesity, Overweight, Osteo Arthritis Knee TRIUMPH-4 was a randomized, double-blind, placebo-controlled Phase 3 trial in 445 adults with obesity or overweight and knee osteoarthritis, who received weekly retatrutide 9 mg or 12 mg or placebo. The two primary endpoints at week 68 were the change in knee pain on the WOMAC pain scale and the percent change in body weight. Pain fell by 4.0 and 3.7 points against 2.1 points with placebo, and weight fell by 20.0% and 23.7% against 4.6% with placebo. The sponsor reports both doses as statistically significant on both endpoints, so the trial met its primary endpoints. The figures come from the company announcement, which does not print p-values. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT05931367 | 3 | Co-primary: change in WOMAC pain subscale score and percent change in body weight from baseline to week 68 2025-11-14 | Co-primary 1, WOMAC pain subscale change to week 68 (treatment-regimen estimand): retatrutide 9 mg -4.0 points (-67.2%), 12 mg -3.7 points (-62.6%) vs placebo -2.1 points (-35.1%); statistically significant for each dose per the sponsor (p not printed), met. Co-primary 2, percent change in body weight to week 68: 9 mg -20.0%, 12 mg -23.7% vs placebo -4.6%; statistically significant for each dose per the sponsor (p not printed), met. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other GLP-1/GIP/glucagon receptor (triple) drugs
UBT251, Efocipegtrutide, HM15275, HRS-4729. Compare all 5 GLP-1/GIP/glucagon receptor (triple) drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Atherosclerotic Cardiovascular Disease: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Retatrutide: this drug | Phase 3 | Peptide | GLP-1/GIP/glucagon receptor (triple) | not yet graded | No reviewed efficacy summary in this indication | |
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | Weak signal | NCT03510884: DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7) NCT01709500: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis (From Baseline to Week 52): Alirocumab 75 mg/up to 150 mg -48.7 percent change (Standard Error 1.9) vs Placebo 2.8 percent change (Standard Error 2.8) | |
| Bempedoic Acid (Nexletol) | Approved | Small molecule | ATP citrate lyase | Partial signal | NCT02991118: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid -15.07 percent change (Standard Error 1.073) vs Placebo 2.35 percent change (Standard Error 1.446) NCT02988115: Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline; Week 12): Bempedoic Acid -22.58% (Standard Error 1.29) vs Placebo -1.17% (Standard Error 1.421) | |
| Bempedoic Acid / Ezetimibe (Nexlizet) | Approved | Small molecule | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe) | Partial signal | NCT03337308: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC -36.2% (Standard Error 2.56) vs Bempedoic Acid 180 mg -17.2% (Standard Error 2.52) vs Ezetimibe 10 mg -23.2% (Standard Error 2.18) vs Placebo 1.8% (Standard Error 3.49) | |
| Cangrelor (Kengreal) | Approved | Small molecule | P2Y12 receptor | Partial signal | NCT00385138: Death, MI or ischemia-driven revascularization at 48 h: 7.0% cangrelor (185/2654) vs 8.0% placebo (210/2641); OR 0.87, 95% CI 0.71 to 1.07; P=0.17. Both arms received clopidogrel 600 mg (CHAMPION PLATFORM, NEJM 2009). missed | |
| Colchicine (cardiovascular) (Lodoco) | Approved | Small molecule | Microtubule/inflammasome (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952 | |
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | not yet graded | No reviewed efficacy summary in this indication | |
| Evolocumab (Repatha) | Approved | Monoclonal antibody | PCSK9 | Partial signal | NCT02392559: Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08) NCT02207634: Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score (Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).): Evolocumab 0.1134 Z score (95% CI 0.0449 to 0.182) vs Placebo 0.1206 Z score (95% CI 0.0535 to 0.1877) | |
| Ezetimibe / Simvastatin (Vytorin) | Approved | Small molecule | HMG-CoA reductase / NPC1L1 | Reliable signal | NCT00202878: Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Ezetimibe/Simvastatin 32.72% (95% CI 31.63 to 33.85) vs Simvastatin 34.67% (95% CI 33.56 to 35.81) NCT00110435: Percent reduction in LDL-C from baseline at 6 weeks: ezetimibe/simvastatin 10/20mg -53.6% vs atorvastatin 10mg -38.3% (P<.001) and vs atorvastatin 20mg -44.6% (P<.001); ezetimibe/simvastatin 10/40mg -57.6% vs atorvastatin 40mg -50.9% (P<.001). Primary endpoint (percent change from baseline in LDL-C) significantly favored ezetimibe/simvastatin at both dose comparisons. | |
| Icosapent Ethyl (Vascepa) | Approved | Small molecule | Omega-3 fatty acid (EPA) | Reliable signal | NCT01492361: Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization. (Total follow-up time of up to approximately 6 years.): AMR101 705/4089 vs Placebo 901/4090 | |
| Liraglutide (Victoza) | Approved | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Semaglutide (Ozempic) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT04560998: Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9% | |
| Semaglutide (Rybelsus) | Approved | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Semaglutide (Wegovy) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 | |
| Ticagrelor (Brilinta) | Approved | Small molecule | P2Y12 receptor | Partial signal | Featured results are non-efficacy only in this race | |
| Tirzepatide (Mounjaro) | Approved | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| AG2304 | Phase 3 | Small molecule | HMG-CoA reductase / NPC1L1 | Partial signal | No reviewed efficacy summary in this indication | |
| Alprostadil | Phase 3 | Small molecule | Prostaglandin E1 receptor | not yet graded | NCT01263925: ClinicalTrials.gov results section for NCT01263925 ('Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication', UCB Pharma, Phase 3, enrollment 561/541 FAS, completed April 2011 -- matches this record exactly). Primary outcome: pain-free walking-distance ratio vs active comparator (pentoxifylline) across three periods; both treatments produced similar improvements with no clear superiority of either. phase 3 result · pivotal pending | |
| Amlodipine / Valsartan / Atorvastatin (CJ-30061) | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / HMG-CoA reductase | Partial signal | No reviewed efficacy summary in this indication | |
| Beperminogene Perplasmid (HGF Plasmid) (Collategene) | Phase 3 | Gene therapy / editing | HGF (hepatocyte growth factor), Hepatocyte growth factor (HGF) | not yet graded | No reviewed efficacy summary in this indication | |
| Cilostazol / Rosuvastatin (UI022 / UI023) | Phase 3 | Small molecule | PDE3 (phosphodiesterase 3) and HMG-CoA reductase | Reliable signal | NCT07600385: KPAQ summary score change (FAS, n=257): test group 15.41 points (SD 14.18) vs control group 10.27 points (SD 14.70); between-group difference 5.14 points (P=0.004), test group superior. | |
| Dalcetrapib | Phase 3 | Small molecule | CETP | Partial signal | NCT00658515: Primary composite cardiovascular endpoint, dalcetrapib vs placebo: hazard ratio 1.04 (95% CI 0.93 to 1.16), P=0.52; trial stopped for futility (NEJM 2012). missed NCT01059682: Nominal Change From Baseline to Study End in Coronary Percent Atheroma Volume (PAV) of the Target Coronary Artery Assessed by IVUS. (24 months): Dalcetrapib 0.6% (Standard Deviation 3.69) vs Placebo 0.5% (Standard Deviation 2.01) | |
| Dapagliflozin (Farxiga / Forxiga) | Phase 3 | Small molecule | SGLT2 | not yet graded | No reviewed efficacy summary in this indication | |
| DWC202206 + DWC202207 | Phase 3 | Small molecule | — | Partial signal | No reviewed efficacy summary in this indication | |
| Ebronucimab | Phase 3 | Monoclonal antibody | PCSK9 | Partial signal | NCT05255094: LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001). | |
| Enlicitide (Lipfendra) | Phase 3 | Peptide | PCSK9 | Reliable signal | NCT05952856: Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001). NCT05952869: Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24): Enlicitide Decanoate -58.2% (Standard Deviation 28) vs Placebo 2.6% (Standard Deviation 23.6) | |
| Ezetimibe (Zetia) | Phase 3 | Small molecule | Dietary Cholesterol Absorption Inhibitor, NPC1L1 | Reliable signal | NCT00092586: Percent change in LDL-C: ezetimibe+statin -25.8% vs placebo+statin -2.7%; treatment difference -23.1 percentage points (P<.001) NCT03867318: Proportion achieving LDL-C goal <=100 mg/dL at Week 14: 22% (ezetimibe 10mg + atorvastatin, n=305) vs 7% (atorvastatin dose-titration alone, n=316); P<.01 | |
| Fimasartan / Atorvastatin / Ezetimibe (BR1017) | Phase 3 | Small molecule | AT1 receptor; NPC1L1; HMG-CoA reductase | Partial signal | NCT05930028: Week 8 co-primary endpoints (full analysis set, 148 randomized): mean sitting systolic BP, fimasartan + atorvastatin/ezetimibe vs atorvastatin/ezetimibe, LS mean difference -7.26 mm Hg (95% CI -12.91 to -1.61), P = 0.0124; LDL-C percent change, fimasartan + atorvastatin/ezetimibe vs fimasartan, LS mean difference -58.02% (95% CI -66.03 to -50.02), P < 0.0001 (Hong et al., Clin Ther 2025). | |
| Hyzetimibe | Phase 3 | Small molecule | NPC1L1 | Partial signal | NCT03433196: LDL-C percent change from baseline (primary endpoint, week 12): -16.39% (95% CI -19.04 to -13.74) with hyzetimibe (HS-25, referred to in this paper as hybutimibe) + atorvastatin vs -6.75% (95% CI -9.48 to -4.02) with atorvastatin alone, P<0.0001 NCT03413462: 第12周试验组LDL-C较基线的变化率为(-10.23±13.58)%,显著优于对照组(4.34±15.88)%。 | |
| Inclisiran (Leqvio) | Phase 3 | RNA / oligonucleotide | PCSK9 | Partial signal | NCT04652726: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -27.14% (95% CI -32.04 to -22.24) vs Part 1 - Placebo 1.4% (95% CI -3.97 to 6.78) NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52) | |
| Laroprovstat | Phase 3 | Small molecule | PCSK9 | Reliable signal | NCT06173570: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo) | |
| Laroprovstat / Rosuvastatin | Phase 3 | Small molecule | PCSK9 (laroprovstat component) + HMG-CoA reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Lepodisiran | Phase 3 | RNA / oligonucleotide | LPA gene / apolipoprotein(a) mRNA | Partial signal | NCT05565742: Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): 16 mg LY3819469 -39.0% ± 7.37 vs 96 mg LY3819469 -74.4% ± 2.16 vs 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) -93.7% ± 0.38 vs Placebo 3.1% ± 8.99; p=<0.001 (16 mg LY3819469 vs Placebo), p=<0.001 (96 mg LY3819469 vs Placebo), p=<0.001 (400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo) | |
| Lerodalcibep (Lerochol) | Phase 3 | Protein / enzyme therapeutic | PCSK9 | Reliable signal | NCT04797104: LDL-C at Week 24: placebo-adjusted reduction of 58.61% (P<.0001); co-primary endpoint, mean of Weeks 22 and 24: placebo-adjusted reduction of 65.0% (P<.0001) NCT05004675: LDL-C change from baseline at Day 270 (mITT): -53% with lerodalcibep vs -45.3% with inclisiran (P=0.0319); per-protocol: -55.4% vs -45.4% (P=0.005) | |
| Maridebart Cafraglutide (MariTide) | Phase 3 | Peptide | GLP-1R agonist; GIPR antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Muvalaplin | Phase 3 | Small molecule | Apolipoprotein(a) [apo(a)] kringle domain / apo(a)-apoB100 interaction | Partial signal | NCT05563246: Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay (Baseline, Week 12): 10 mg LY3473329 -47.35% ± 4.811 vs 60 mg LY3473329 -81.57% ± 1.230 vs 240 mg LY3473329 -85.71% ± 0.927 vs Placebo 0.48% ± 6.382; p=<.001 (10 mg LY3473329 vs Placebo), p=<.001 (60 mg LY3473329 vs Placebo), p=<.001 (240 mg LY3473329 vs Placebo) | |
| NL003 | Phase 3 | Gene therapy / editing | Hepatocyte growth factor (HGF) | not yet graded | No reviewed efficacy summary in this indication | |
| Obicetrapib | Phase 3 | Small molecule | CETP | Partial signal | NCT05142722: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10mg -29.94% (Standard Error 1.104) vs Placebo 2.7% (Standard Error 1.571) NCT05425745: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10 mg -36.05% (Standard Error 1.769) vs Placebo 0.25% (Standard Error 2.48) | |
| Obicetrapib / Ezetimibe (Evlarco) | Phase 3 | Small molecule | CETP, NPC1L1 | Partial signal | NCT06005597: Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564) | |
| Olpasiran | Phase 3 | RNA / oligonucleotide | LPA gene / apolipoprotein(a) mRNA | Partial signal | NCT04270760: Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 (Baseline and Week 36): Group 1: Olpasiran 10 mg Q12W -66.91% ± 1.78 vs Group 2: Olpasiran 75 mg Q12W -93.78% ± 1.78 vs Group 3: Olpasiran 225 mg Q12W -97.53% ± 1.82 vs Group 4: Olpasiran 225 mg Q24W -96.89% ± 1.85 vs Group 5: Placebo Q12W 3.60% ± 1.89; p=<0.001 (Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W), p=< 0.001 (Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W) | |
| Ongericimab (Junshida) | Phase 3 | Monoclonal antibody | PCSK9 | Reliable signal | NCT05325203: Percent change in LDL-C from baseline to week 24 (JS002-005/NCT05325203, HeFH, 135 patients): ongericimab 150mg Q2W -69.4% vs placebo (p<0.0001); ongericimab 450mg Q4W -80.6% vs placebo (p<0.0001) NCT04781114: LDL-C percentage change from baseline to week 24 vs placebo: 150 mg Q2W -67.7% (95% CI -72.5% to -63.0%; P<0.0001); 300 mg Q4W -61.2% (95% CI -67.1% to -55.2%; P<0.0001). | |
| Orforglipron (Foundayo) | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Pelacarsen | Phase 3 | RNA / oligonucleotide | Apolipoprotein(a) mRNA | Partial signal | NCT05305664: Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule (Up to Week 52): Pelacarsen (TQJ230) 0.16 Apheresis sessions received per week (IQR 0.04 to 0.25) vs Placebo 0.93 Apheresis sessions received per week (IQR 0.9 to 1) | |
| Pemafibrate (Parmodia) | Phase 3 | Small molecule | PPAR-alpha | Partial signal | No reviewed efficacy summary in this indication | |
| PMR (cilostazol ER) | Phase 3 | Small molecule | Phosphodiesterase 3 (PDE3) | Weak signal | No reviewed efficacy summary in this indication | |
| Pravafenix | Phase 3 | Small molecule | HMG-CoA reductase / PPAR-alpha | Partial signal | No reviewed efficacy summary in this indication | |
| QLC7401 | Phase 3 | RNA / oligonucleotide | PCSK9 | not yet graded | No reviewed efficacy summary in this indication | |
| Ranolazine | Phase 3 | Small molecule | Cardiac late sodium current (late INa, Nav1.5) | Partial signal | NCT00099788: The primary end point occurred in 696 patients (21.8%) in the ranolazine group and 753 patients (23.5%) in the placebo group (hazard ratio 0.92). missed NCT01562041: Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index (Baseline up to Day 15): Ranolazine 500 mg — Test 1: 3.211 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.6553); Test 2: 2.822 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0289); Test 3: 3.228 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.891); Test 4: 2.502 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.8884); Change From Baseline in Maximum ST/Heart Rate Index: -0.605 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0482) | |
| Recaticimab | Phase 3 | Monoclonal antibody | PCSK9 | Reliable signal | NCT04844125: Change in LDL-C from baseline at Week 12: -54.4% recaticimab vs -4.5% placebo; treatment difference -49.8 percentage points (95% CI -55.8 to -43.9), P<0.0001 NCT04849000: LDL-C reduction vs placebo at the primary endpoint timepoint: 150 mg Q4W -49.6% (95% CI 44.2-54.9%); 300 mg Q8W -52.8% (95% CI 48.3-57.2%); 450 mg Q12W -45.0% (95% CI 41.0-49.0%); P<0.0001 for all comparisons. | |
| Ribupatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| SAL003 | Phase 3 | Monoclonal antibody | PCSK9 | Partial signal | No reviewed efficacy summary in this indication | |
| Sarpogrelate (Anplag) | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Sumecigrel | Phase 3 | Small molecule | P2Y12 platelet receptor | Partial signal | NCT03599284: Primary, inhibition of ADP-induced platelet aggregation (%IPA) at day 28: vicagrel 20/5 mg 30.19%, 24/6 mg 35.02%, 30/7.5 mg 45.61%, clopidogrel 32.55%; the paper reports these as comparable across all groups (P=0.0694) and sets no non-inferiority margin. | |
| SYH2053 | Phase 3 | RNA / oligonucleotide | PCSK9 | Partial signal | No reviewed efficacy summary in this indication | |
| Tafolecimab (Sintbilo) | Phase 3 | Monoclonal antibody | PCSK9 | Reliable signal | NCT04289285: LDL-C percent change from baseline to week 48, treatment difference vs placebo: -65.0% (97.5% CI: -70.2%, -59.9%) for tafolecimab 450 mg Q4W; -57.3% (97.5% CI: -64.0%, -50.7%) for 600 mg Q6W; both P < 0.0001 NCT04709536: Percent change in LDL-C from baseline to Week 12: tafolecimab -68.9% (SE 1.4%) vs placebo -5.8% (SE 1.8%); treatment difference -63.0% (95% CI -66.5% to -59.6%, P<0.0001) | |
| Ziltivekimab | Phase 3 | Monoclonal antibody | Interleukin-6 | Partial signal | NCT05021835: 3-point MACE (CV death, non-fatal MI, non-fatal stroke): HR 0.99 (95% CI 0.88-1.11) for ziltivekimab vs placebo. missed | |
| Neovasculgen | Phase 2/3 | Gene therapy / editing | VEGF165 gene therapy (angiogenic plasmid) | Partial signal | NCT03068585: Pain-free walking distance increased in the pCMV-vegf165 (Neovasculgen) treatment group by 110.4% at 6 months, versus no positive results in the standard-treatment control group | |
| ABP-745 | Phase 2 | Small molecule | NLRP3 inflammasome | not yet graded | No reviewed efficacy summary in this indication | |
| ACP-01 | Phase 2 | Biologic (subtype unspecified) | Autologous angiogenic cell precursor (ACP) therapy | Partial signal | NCT02551679: Primary composite (de-novo gangrene, doubling of wound size, major amputation or death within 1 year): 12 of 46 participants on ACP-01 vs 3 of 21 on placebo, hazard ratio 2.046 (95% CI 0.577 to 7.255), p=0.258 (CT.gov posted results). missed | |
| Berberine Ursodeoxycholate (HTD1801) | Phase 1/2 | Small molecule | AMPK pathway / NLRP3 inflammasome (dual) | Weak signal | NCT03381287: Day 28, 2000 mg/day (highest dose) vs placebo: total cholesterol -8.2% (P=0.0004); LDL-C -10.4% (P=0.0006). Lower doses (500 mg, 1000 mg) did not reach significance. | |
| ALN-ANG3 | Phase 1 | RNA / oligonucleotide | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 62 furthest-along competitors are listed; 61 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow retatrutide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
November 2026 (1)
What to watch
2027 (4)
January 2027 (1)
What to watch
March 2027 (1)
June 2027 (1)
What to watch
September 2027 (1)
What to watch
2028 (2)
2029 (1)
February 2029 (1)
What to watch
2030 (1)
August 2030 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent